Blue Trust Inc. Cuts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Blue Trust Inc. trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 62.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 538 shares of the medical equipment provider’s stock after selling 896 shares during the quarter. Blue Trust Inc.’s holdings in Lantheus were worth $48,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC boosted its position in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Lantheus by 4,324.9% in the 3rd quarter. International Assets Investment Management LLC now owns 66,948 shares of the medical equipment provider’s stock worth $7,348,000 after purchasing an additional 65,435 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Lantheus during the 3rd quarter valued at about $1,863,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Lantheus during the third quarter valued at about $849,000. Finally, DekaBank Deutsche Girozentrale increased its holdings in shares of Lantheus by 7.9% in the third quarter. DekaBank Deutsche Girozentrale now owns 10,551 shares of the medical equipment provider’s stock worth $1,121,000 after purchasing an additional 768 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is owned by company insiders.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $80.07 on Wednesday. Lantheus Holdings, Inc. has a 1 year low of $56.44 and a 1 year high of $126.89. The firm has a 50-day simple moving average of $89.77 and a two-hundred day simple moving average of $96.81. The company has a market cap of $5.57 billion, a P/E ratio of 13.32 and a beta of 0.44.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.